Physician profile
Nadia M Elsayed
NPI 1821314659
$6,888.50
in general payments reported to CMS, 2019-2025
42 companies · $1,199 in 2025
The $1,199 reported for 2025 was more than what 87% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,335 · 2022: $1,932 · 2023: $1,822 · 2024: $600 · 2025: $1,199.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,622.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,621.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $954.23 | 2021-2025 | Fasenra, Lokelma, Farxiga |
| Sk Life Science, INC. | $451.30 | 2021-2023 | Xcopri |
| Coloplast Corp | $421.46 | 2022-2025 | Titan |
| Abbvie INC. | $356.50 | 2022-2025 | |
| Amgen INC. | $266.42 | 2022-2024 | |
| Alexion Pharmaceuticals, INC. | $220.33 | 2022-2023 | |
| Gilead Sciences, INC. | $220.05 | 2023 | Epclusa |
| Vifor Pharma, INC. | $216.91 | 2021-2022 | |
| Medtronic, INC. | $192.14 | 2022-2023 | Pipeline |
| Neurocrine Biosciences, INC. | $176.76 | 2022-2023 | Ingrezza |
| Novo Nordisk INC | $165.54 | 2024-2025 | Wegovy |
| Abbott Laboratories | $145.75 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $133.56 | 2022 | |
| Genzyme Corporation | $129.22 | 2025 | |
| Neurelis, INC. | $127.77 | 2023 | Valtoco |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nadia Elsayed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.